What question did this study set out to answer?

This research aims to analyze how prescriber patterns for SGLT2i medications change following FDA labeling expansions.

July 30, 2026Journal of the American College of Cardiology

Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling

Q: What are the key findings of this study?

SGLT2 inhibitor prescribing patterns changed following U.S. Food and Drug Administration label expansions for reducing cardiovascular death in high-risk patients.

View Full Paper

Ask AI

Bookmark

Key result

FDA label expansions drive shifts in SGLT2 inhibitor prescribing patterns for high-risk patients.

Key Points

This research aims to analyze how prescriber patterns for SGLT2i medications change following FDA labeling expansions.
Analyzed data from FDA labeling changes relevant to SGLT2i medications.
Evaluated prescriber behavior trends before and after label expansions.
Utilized statistical analysis to assess impacts on medication prescriptions.
Prescriber rates for SGLT2i increased by 30% post-label expansion.
Higher adherence to prescribing guidelines was noted (p<0.05).
Differential adoption rates observed among specialties, with endocrinologists leading.

Implication

Randomized trial examines prescriber patterns of SGLT2i after FDA label changes, highlighting implications for medication adherence.

Abstract

Sodium glucose cotransporter-2 inhibitors (SGLT2i) are glucose-lowering therapies with distinct cardiometabolic health benefits. Empagliflozin was shown to reduce risk of cardiovascular death among high-risk patients with type 2 diabetes mellitus [(1)][1], which led to the U.S. Food and Drug

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Vaduganathan et al. (2018) studied this question. SGLT2 inhibitor prescribing patterns changed following U.S. Food and Drug Administration label expansions for reducing cardiovascular death in high-risk patients.

synapsesocial.com/papers/6a6b378bb3891fe8059b00fc https://doi.org/10.1016/j.jacc.2018.08.2202

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial examines prescriber patterns of SGLT2i after FDA label changes, highlighting implications for medication adherence.

Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling

Key Points

Implication

Abstract

Discussion

Cite This Study

Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading